CLINICAL TRIALS PROFILE FOR FENTORA
✉ Email this page to a colleague
All Clinical Trials for Fentora
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00387010 ↗ | Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain | Terminated | Cephalon | Phase 3 | 2006-12-01 | The primary purpose of the study is to evaluate the impact of treatment with fentanyl buccal tablets on the anxiety symptoms commonly associated with chronic pain in patients with breakthrough pain (BTP). Other purposes are to assess the management of BTP, to evaluate patient functioning, and to determine any influences on the successful dose achieved. |
| NCT00685295 ↗ | Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain | Completed | Massachusetts General Hospital | Phase 1/Phase 2 | 2008-08-01 | Assess whether transbuccal fentanyl provides more rapid relief of orthopedic pain, than does the comparator Percocet |
| NCT00842829 ↗ | Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients | Terminated | Cephalon | Phase 4 | 2009-01-01 | Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. Fentanyl Buccal Tablet (FBT) is used for the treatment of BTP in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. FBT treatment should be individually titrated to an effective dose that provides adequate analgesia and minimizes undesirable effects. To reach the safest effective dose for the individual patient as soon as possible, the dose titration process is critical. The aim of this study, conducted under pragmatic conditions in a large-scale population of cancer patients is to compare the proportion of patients reaching an effective FBT dose after titration starting with either a 100 mcg dose or a 200 mcg dose. |
| NCT01007773 ↗ | Safety of Dexmedetomidine in Severe Traumatic Brain Injury | Withdrawn | Hospira, Inc. | Phase 2 | 2010-01-01 | The aim of this study is to assess the safety and feasibility of dexmedetomidine as an adjunct to conventional sedative therapy compared to conventional sedative therapy alone in patients with severe traumatic brain injury. |
| NCT01007773 ↗ | Safety of Dexmedetomidine in Severe Traumatic Brain Injury | Withdrawn | Hospira, now a wholly owned subsidiary of Pfizer | Phase 2 | 2010-01-01 | The aim of this study is to assess the safety and feasibility of dexmedetomidine as an adjunct to conventional sedative therapy compared to conventional sedative therapy alone in patients with severe traumatic brain injury. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Fentora
Condition Name
Clinical Trial Locations for Fentora
Trials by Country
Clinical Trial Progress for Fentora
Clinical Trial Phase
Clinical Trial Sponsors for Fentora
Sponsor Name
